Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home. The once ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...

Pfizer Inc. (NYSE: PFE) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound ...